Viral vectors, such as adeno-associated viruses (AAV) and lentiviral viruses (LVV), are recently at the forefront of biotherapeutic development for the support of cell and gene therapies. As with ...

With up to 2.4 million U.S. cases and over 250 million chronic cases globally, hepatitis B infection persists despite the availability of a vaccine. Vaccines work by immunizing the body against a ...

(Nanowerk News) Bioengineers have found a way to program the size and shape of virus particles by combining viral protein building blocks and templates made from DNA. The resulting nanostructures ...

This is a preview. Log in through your library . Abstract Background. Naturally occurring variants of human papillomavirus (HPV) 58 have been defined as lineages and sublineages but little is known ...

Key PointsResearch on HIV's conical capsid that began over 25 years ago led to the development of lenacapavir, the world's first capsid inhibitor.In ...

Though treatments are available, there is no cure or vaccine from HIV, which impacts about 38 million people worldwide. It's difficult to target the RNA genome of the HIV virus in part because it ...

In order for HIV to replicate, the viral genome must enter into the cell nucleus and integrate into the host cell chromosome. Previous work suggests that the entry proceeds through nuclear pore ...

The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

Proteins are responsible for many of the biological functions that make life possible. Michigan Tech researchers are gaining a better understanding of how they affect our day-to-day existence, vaccine ...

High-quality HIV antigens for cutting-edge solutions. On February 18, 2025, Gilead Sciences (CA, US) announced a significant milestone: the US FDA accepted their New Drug Applications (NDAs) for ...